Sinomenine, a COX-2 inhibitor, induces cell cycle arrest and inhibits growth of human colon carcinoma cells in vitro and in vivo

Oncology Letters

Volumn 11, Issue 1, 2016, Pages 411-418

  Yang, Haibo ^a   Yin, Peihao ^a   Shi, Zhan ^a   Ma, Yanchun ^a   Zhao, Chenggen ^a   Zheng, Jampu ^a   Chen, Teng ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cell cycle; Colorectal cancer; Cyclooxygenase 2; Sinomenine; SW1116 cells; Xenograft tumor

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; MESSENGER RNA; PROTEIN P21; PROTEIN P27; SINOMENINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL ULTRASTRUCTURE; CELL VIABILITY ASSAY; CHEMILUMINESCENCE IMMUNOASSAY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG MEGADOSE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MORTALITY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TOXICITY TESTING; TRANSMISSION ELECTRON MICROSCOPY; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84948773881     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3838     Document Type: Article

References (37)

1. Ekberg M, Callender M, Hamer H and Rogers S: Exploring the decision to participate in the national health service bowel cancer screening programme. Eur J Cancer Prev 23: 391-397, 2014.
2. Hou L, Jiang J, Liu B, Nasca PC, Wu Y, Zou X, Han W, Chen Y, Zhang B, Xue F, et al: Association between smoking and deaths due to colorectal malignant carcinoma: a national population-based case-control study in China. Br J Cancer 110: 1351-1358, 2014.
3. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001.
4. Chatenoud L, Bertuccio P, Bosetti C, Malvezzi M, Levi F, Negri E and La Vecchia C: Trends in mortality from major cancers in the Americas: 1980-2010. Ann Oncol 25: 1843-1853, 2014.
5. Zaniboni A and Labianca R; Gruppo Italiano per lo Studio e la Cura dei Tumori del Digerente: Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann Oncol 15: 1310-1318, 2004.
6. Rao S and Cunningham D: Adjuvant therapy for colon cancer in the new millenium. Scand J Surg 92: 57-64, 2003.
7. Sinha VR and Honey C: Critical aspects in rationale design of fluorouracil-based adjuvant therapies for the management of colon cancer. Crit Rev Ther Drug Carrier Syst 29: 89-148, 2012.
8. Lotfi-Jam K, Carey M, Jefford M, Schofield P, Charleson C and Aranda S: Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol 26: 5618-5629, 2008.
9. Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J and Conaghan PG: Value of information in the osteoarthritis setting: Cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors. Pharmacoeconomics 29: 225-237, 2011.
10. Jacobo-Herrera NJ, Pérez-Plasencia C, Camacho-Zavala E, González GF, Urrutia EL, García-Castillo V and Zentella-Dehesa A: Clinical evidence of the relationship between aspirin and breast cancer risk (review). Oncol Rep 32: 451, 2014.
11. Brasky TM, Liu J, White E, et al: Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women’s Health Initiative. Int J Cancer 135: 1869-1883, 2014.
12. Wu X, Cai M, Ji F and Lou LM: The impact of COX-2 on invasion of osteosarcoma cell and its mechanism of regulation. Cancer Cell Int 14: 27, 2014.
13. Liggett JL, Zhang X, Eling TE and Baek SJ: Anti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targets. Cancer Lett 346: 217-224, 2014.
14. Davies NM and Jamali F: COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharm Sci 7: 332-336, 2004.
15. Zhang MF, Zhao Y, Jiang KY, et al: Comparative pharmacokinetics study of sinomenine in rats after oral dministration of sinomenine monomer and sinomenium acutum extract. Molecules 19: 12065-12077, 2014.
16. Gao T, Hao J, Wiesenfeld-Hallin Z, et al: Analgesic effect of sinomenine in rodents after inflammation and nerve injury. Eur J Pharmacol 721: 5-11, 2013.
17. Mo ZX, An SL and Zhou JY: Effects of caulis sinomenii and sinomenine on morphine-induced place preference and brain histamine level in mice. Nan Fang Yi Ke Da Xue Xue Bao 26: 1709-1713, 2006 (In Chinese).
18. Yamasaki H: Pharmacology of sinomenine, an anti-rheumatic alkaloid from sinomenium acutum. Acta Med Okayama 30: 1-20, 1976.
19. Candinas D, Mark W, Kaever V, et al: Immunomodulatory effects of the alkaloid sinomenine in the high responder ACI-to-Lewis cardiac allograft model. Transplantation 62: 1855-1860, 1996.
20. Jiang T, Zhou L, Zhang W, Qu D, Xu X, Yang Y and Li S: Effects of sinomenine on proliferation and apoptosis in human lung cancer cell line NCI-H460 in vitro. Mol Med Rep 3: 51-56, 2010.
21. Zhou L, Luan H, Liu Q, Jiang T, Liang H, Dong X and Shang H: Activation of PI3K/Akt and ERK signaling pathways antagonized sinomenine-induced lung cancer cell apoptosis. Mol Med Rep 5: 1256-1260, 2012.
22. Kues WA, Anger M, Carnwath JW, et al: Cell cycle synchronization of porcine fetal fibroblasts: effects of serum deprivation and reversible cell cycle inhibitors. Biol Reprod 62: 412-419, 2000.
23. Chen M, Huang J, Yang X, et al: Serum starvation induced cell cycle synchronization facilitates human somatic cells reprogramming. PLoS One 7: e28203, 2012.
24. Tan Y, Sun X, Xu M, et al: Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Clin Cancer Res 5: 2157-2163, 1999.
25. Tjandrawinata RR, Dahiya R and Hughes-Fulford M: Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 75: 1111-1118, 1997.
26. Maekawa M, Sugano K, Sano H, et al: Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps. Jpn J Clin Oncol 28: 421-426, 1998.
27. Hao X, Bishop AE, Wallace M, et al: Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 187: 295-301, 1999.
28. Sheehan KM, Sheahan K, O’Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ and Murray FE: The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282: 1254-1257, 1999.
29. Kõivomägi M and Skotheim JM: Docking interactions: cell-cycle regulation and beyond. Curr Biol 24: R647-R649, 2014.
30. Dorée M and Hunt T: From Cdc2 to Cdk1: when did the cell cycle kinase join its cyclin partner? J Cell Sci 115: 2461-2464, 2002.
31. Sherr CJ and Roberts JM: Living with or without cyclins and cyclin-dependent kinases. Genes Dev 18: 2699-2711, 2004.
32. Fisher D, Krasinska L, Coudreuse D and Novák B: Phosphorylation network dynamics in the control of cell cycle transitions. J Cell Sci 125: 4703-4711, 2012.
33. Yoon MK, Mitrea DM, Ou L and Kriwacki RW: Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans 40: 981-988, 2012.
34. Weinberg WC and Denning MF: P21Waf1 control of epithelial cell cycle and cell fate. Crit Rev Oral Biol Med 13: 453-464, 2002.
35. Shankland SJ and Wolf G: Cell cycle regulatory proteins in renal disease: Role in hypertrophy, proliferation and apoptosis. Am J Physiol Renal Physiol 278: F515-F529, 2000.
36. Todd R, Hinds PW, Munger K, Rustgi AK, Opitz OG, Suliman Y and Wong DT: Cell cycle dysregulation in oral cancer. Crit Rev Oral Bio Med 13: 51-61, 2002.
37. Schafer KA: The cell cycle: a review. Vet Pathol 35: 461-478, 1998.